Neuren Pharmaceuticals(ASX:NEU)
Developing drug therapies forserious neurological disorders that emerge in early childhood &have no or limited treatment options
Highly successful US launchof DAYBUE™ (trofinetide) for Rett syndrome by partner Acadia
2023 net sales of US$177.2m;A$27m NEU royalties
1Q24 net sales US$75.9;A$11.6m royalties
2024 net sales guidance ofUS$370-420m; would earn NEU A$61-70m + A$77m sales milestone
Acadia advancingDAYBUE™ in Canada, Europe & Japan
NNZ-2591 in Phase 2 trialsfor four syndromes; 5x Rett market
All indications received FDAinvestigational new drug (IND) & orphan drug designation
Pitt Hopkins topline resultsexpected 2Q24, Angelman results expected 3Q24
Dec'23: PMS demonstratedsignificantly positive results, preparation underway for FDA end of Ph2 meeting
$243.1m cash as of 31 Mar'24
Market cap ~ $2.58B
Neuren Media and Analyst Coverage, page-963
-
- There are more pages in this discussion • 154 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.94 |
Change
-0.040(0.20%) |
Mkt cap ! $2.548B | |||
| Open | High | Low | Value | Volume |
| $19.92 | $20.04 | $19.51 | $4.745M | 239.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 198 | $19.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.94 | 1256 | 2 |
View Market Depth
| Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |